Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic. — Lecanemab and donanemab are the first anti-Aβ treatments to receive approval in Europe. Eligibility criteria are strict, eg., APOE ε4/4 carriers are...

Evidence span

Preparing for the implementation of anti-amyloid therapies in Europe: Assessing real-world eligibility for lecanemab and donanemab in a Swedish memory clinic. — Lecanemab and donanemab are the first anti-Aβ treatments to receive approval in Europe. Eligibility criteria are strict, eg., APOE ε4/4 carriers are...

From Rosenberg A et al. 2026, The journal of prevention of Alzheimer's disease

Method & conditions

Evidence type

experimental

Method

manual state transition; control details require source inspection

Species

Homo sapiens

Conditions

Humans; Alzheimer Disease; Aged; Aged, 80 and over; Middle Aged — The journal of prevention of Alzheimer's disease 2026

Replicated

not yet

Confidence basis

operator-supplied frontier prior; review required